Roche Signs a License Agreement with Arrakis Therapeutics for the Discovery of RNA-Targeted Small Molecule Therapies

 Roche Signs a License Agreement with Arrakis Therapeutics for the Discovery of RNA-Targeted Small Molecule Therapies

Shots:

  • Arrakis to receive $190M up front in cash and is eligible to get several billion dollars in pre/clinical and commercial milestones along with royalties for products emerging from the collaboration
  • Arrakis will be responsible for discovery and research activities of each target to a defined point while Roche will get right to exclusively pursue further pre/ clinical development
  • The collaboration will leverage Roche’s rSM discovery platform to discover novel therapies targeting all Roche’s research and development areas

Click here ­to­ read full press release/ article | Ref: Businesswire | Image: Business wire

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post